Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
Follow SNTI
Senti Biosciences, Inc. (SNTI) EV/Sales
As of 16 October 2026, Senti Biosciences, Inc. (SNTI) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −27.8× (September 2022) to 33.0× (October 2022); the current reading is higher than 68% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.7× | — |
| FY2023 | −2.5× | — |
| FY2022 | −13.9× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 21.3× | 238.74% |
| Mar 2026 | 6.3× | — |
| Sep 2023 | −7.7× | — |
| Jun 2023 | −7.8× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APRE Aprea Therapeutics, Inc. compare | −35.7× |
| IMRN IMMURON compare | −3.5× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.3× |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| BOLT Bolt Biotherapeutics, Inc. compare | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)